Citigroup
CABA icon

Citigroup’s Cabaletta Bio CABA Stock Holding History

Citigroup’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Buy
184,232
+156,759
+571% +$516K ﹤0.01% 3825
2026
Q1 		$73.9K Sell
27,473
-46,301
-63% -$129K ﹤0.01% 4383
2025
Q4 		$162K Buy
73,774
+73,422
+20,859% +$182K ﹤0.01% 4093
2025
Q3 		$824 Sell
352
-62,147
-99% -$107K ﹤0.01% 5655
2025
Q2 		$95K Buy
62,499
+31,037
+99% +$48.4K ﹤0.01% 4427
2025
Q1 		$43.6K Sell
31,462
-4,292
-12% -$9.14K ﹤0.01% 4912
2024
Q4 		$81.2K Buy
35,754
+1,188
+3% +$4.17K ﹤0.01% 4930
2024
Q3 		$163K Buy
34,566
+11,672
+51% +$67.5K ﹤0.01% 4485
2024
Q2 		$171K Sell
22,894
-278,992
-92% -$3.42M ﹤0.01% 3970
2024
Q1 		$5.15M Buy
301,886
+215,340
+249% +$4.62M ﹤0.01% 1685
2023
Q4 		$1.96M Buy
86,546
+36,851
+74% +$620K ﹤0.01% 2252
2023
Q3 		$756K Buy
49,695
+42,078
+552% +$575K ﹤0.01% 2737
2023
Q2 		$98.3K Sell
7,617
-38,135
-83% -$414K ﹤0.01% 4262
2023
Q1 		$378K Buy
+45,752
New +$428K ﹤0.01% 3320
2022
Q4 		– Sell
-340
Closed – – 5790
2022
Q3 		$0 Sell
340
-97
-22% -$117 ﹤0.01% 5861
2022
Q2 		$0 Sell
437
-1,359
-76% -$1.92K ﹤0.01% 6260
2022
Q1 		$4K Sell
1,796
-667
-27% -$1.74K ﹤0.01% 5877
2021
Q4 		$9K Buy
2,463
+466
+23% +$4.97K ﹤0.01% 5576
2021
Q3 		$24K Buy
1,997
+486
+32% +$4.48K ﹤0.01% 5149
2021
Q2 		$13K Buy
1,511
+196
+15% +$1.93K ﹤0.01% 5526
2021
Q1 		$15K Sell
1,315
-3,049
-70% -$37.2K ﹤0.01% 5397
2020
Q4 		$54K Buy
4,364
+3,243
+289% +$42.1K ﹤0.01% 5972
2020
Q3 		$12K Sell
1,121
-1,084
-49% -$12.5K ﹤0.01% 6493
2020
Q2 		$25K Buy
2,205
+300
+16% +$2.3K ﹤0.01% 6431
2020
Q1 		$14K Buy
1,905
+597
+46% +$8.18K ﹤0.01% 6882
2019
Q4 		$18K Buy
+1,308
New +$15.5K ﹤0.01% 6970

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citigroup's CABA Position: Q2 2026 in Review

Citigroup increased its Cabaletta Bio (CABA) stake by 571% in Q2 2026, buying an estimated $516K and bringing the position to 184,232 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #3825.

Citigroup first reported a position in CABA in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.15M in Q1 2024. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Citigroup held 184,232 shares of Cabaletta Bio worth $573K as of Q2 2026.
  • Citigroup bought 156,759 Cabaletta Bio shares in Q2 2026, an estimated $516K.
  • Cabaletta Bio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3825 holding.
  • Citigroup first reported a position in Cabaletta Bio in Q4 2019 and has held it in 26 quarters since.
  • Citigroup's Cabaletta Bio position peaked at $5.15M in Q1 2024.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.